Brief: Radiopharm Theranostics Says Australia's Nuclear Science And Technology Organisation Deal
22/11/2022 24:02
Nov 22 (Reuters) - Radiopharm Theranostics RAD.AX :
* AGREEMENT WITH AUSTRALIA'S NUCLEAR SCIENCE AND TECHNOLOGY
ORGANISATION
* DEAL TO SUPPLY COMPANY WITH ISOTOPE NON-CARRIER-ADDED
LUTETIUM-177 (LU-177) FOR ITS TRIALS IN AUSTRALIA
Source text for Eikon: ID:nASXbVFmCX
Further company coverage: RAD.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Radiopharm Theranostics
See all newsBrief: Radiopharm Theranostics Advances To Cohort 3 In 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
Brief: Radiopharm Theranostics And Siemens Healthineers Sign Clinical Supply Agreement For Rad101 In The U.S.
Brief: Radiopharm Theranostics Says RAD And Siemens Sign Clinical Supply Agreement For Rad101
Brief: Radiopharm Theranostics Doses First Patient In Phase 1/2A Clinical Study Of Betabart
Brief: Radiopharm Theranostics Says Co Increases Ownership In Radiopharm Ventures To 87.5%